Literature DB >> 10364704

Renal cell carcinoma and paraneoplastic IgA nephropathy.

T Magyarlaki1, B Kiss, I Buzogány, A Fazekas, F Sükösd, J Nagy.   

Abstract

Paraneoplastic nephropathy is rarely associated with human tumors. Little is known about the pathogenetic background of this relationship. To our knowledge, no conclusive study of the association of potentially 'immunogenic' renal cell carcinoma (RCC) and paraneoplastic nephropathy has been published. For this reason, we performed an immunohistochemical analysis of native resected kidneys of 60 patients with RCC, paying special attention to their pre- and postoperative records. Sixteen (27%) of the 60 tumor patients had immune complex nephropathy (11 IgA nephropathy [IgA NP] and 5 focal segmental glomerulosclerosis [FSGS]). Preoperative proteinuria and/or hematuria observed in 11 of 16 cases disappeared in 6 IgA NP patients within a 2- to 3-month follow-up after nephrectomy. Eleven of 16 tumors stained with the anti human immunoglobulin (IgA or IgM) of the same isotype as that present in glomerular immune complexes. In 3 IgA NP patients RCC-associated von Hippel-Lindau (VHL) protein and IgA staining were found simultaneously in the tumor and glomeruli, with the clinical and laboratory findings disappearing after nephrectomy. Immune injury of the glomeruli due to a tumor-induced antigen-antibody response was demonstrated in these 3 IgA NP patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10364704     DOI: 10.1159/000045388

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  10 in total

Review 1.  Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis.

Authors:  Yeong-Hau H Lien; Li-Wen Lai
Journal:  Nat Rev Nephrol       Date:  2010-12-14       Impact factor: 28.314

2.  Focal segmental glomerulosclerosis in kidney resected for renal cell carcinoma.

Authors:  A Ahsan Ejaz; Xochi J Geiger; Andrew Wasiluk
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

3.  IgA nephropathy associated with Hodgkin's disease in children: a case report, literature review and urinary proteome analysis.

Authors:  Sookkasem Khositseth; Nonglak Kanitsap; Naree Warnnissorn; Visith Thongboonkerd
Journal:  Pediatr Nephrol       Date:  2006-12-02       Impact factor: 3.714

4.  Interleukin 10-expressing B cells inhibit tumor-infiltrating T cell function and correlate with T cell Tim-3 expression in renal cell carcinoma.

Authors:  Chen Cai; Jin Zhang; Minyu Li; Zhen-Jie Wu; Ken H Song; Tina W Zhan; Lin-Hui Wang; Ying-Hao Sun
Journal:  Tumour Biol       Date:  2015-12-30

5.  Prognostic histological and immune markers of renal cell carcinoma.

Authors:  T Magyarlaki; I Buzogány; L Kaiser; F Sükösd; R Döbrönte; B Simon; A Fazekas; J Nagy
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

6.  Specific von Hippel-Lindau protein expression of clear cell renal cell carcinoma with "immunogenic" features.

Authors:  T Magyarlaki; I Buzogány; J Nagy
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

Review 7.  Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients.

Authors:  Aleksandra Semeniuk-Wojtaś; Arkadiusz Lubas; Rafał Stec; Cezary Szczylik; Stanisław Niemczyk
Journal:  Int J Mol Sci       Date:  2016-12-09       Impact factor: 5.923

8.  A case of arteriovenous fistula after renal biopsy in an IgA nephropathy patient with macroscopic hematuria.

Authors:  Satoshi Horikoshi; Akiko Takahata; Akihiko Shiraishi; Hiromitsu Fukuda; Isao Ohsawa; Ryohei Kuwatsuru; Yasuhiko Tomino
Journal:  Case Rep Nephrol Urol       Date:  2013-05-17

9.  Paraneoplastic proteinuria in papillary renal cell carcinoma; a case report.

Authors:  Fatemeh Yaghoubi; Maliheh Yarmohammadi; Mohammad Vasei
Journal:  J Renal Inj Prev       Date:  2016-08-03

10.  Quantification of cancer risk in glomerulonephritis.

Authors:  James Goya Heaf; Alastair Hansen; Gunnar Hellmund Laier
Journal:  BMC Nephrol       Date:  2018-02-02       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.